Begüm Irmak Ön

The validation of prediction models deserves more recognition

Ulrich Mansmann, Begüm Irmak Ön

nl, de (code pays fourni par la source)

External validation of a multiple sclerosis treatment decision score using data from the ProVal-MS cohort study

Stefan Buchka, Alexander Hapfelmeier, Jan Stefan Kirschke, Verena Steuerwald et autres

Background: The course of relapsing-remitting multiple sclerosis (RRMS), frequently preceded by the clinically isolated syndrome (CIS), is variable and challenging to predict. Given many treatment options available, prognostic algorithms are gaining importance in informing initial treatment decisions. However, to date, only a …

nl, de (code pays fourni par la source)

Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis

Begüm Irmak Ön, Joachim B. Havla, Ulrich Mansmann

BACKGROUND: The individual treatment response in people with relapsing-remitting multiple sclerosis (RRMS) remain unpredictable. In order to support medical decisions, we aimed to predict response to fingolimod compared to placebo, by developing and validating prognostic multivariable models. METHODS: We included two-year follow-up …

nl, de (code pays fourni par la source)

Prognostic models in multiple sclerosis: progress and challenges in clinical integration

Joachim B. Havla, Kelly A. Reeve, Begüm Irmak Ön, Ulrich Mansmann et autres

As a chronic inflammatory disease of the central nervous system, multiple sclerosis (MS) is of great individual health and socio-economic significance. To date, there is no prognostic model that is used in routine clinical care to predict the very heterogeneous course of …

de, ch (code pays fourni par la source)

Framework for personalized prediction of treatment response in relapsing-remitting multiple sclerosis: a replication study in independent data

Anna Maria Sakr, Ulrich Mansmann, Joachim B. Havla, Begüm Irmak Ön

BACKGROUND: Individualizing and optimizing treatment of relapsing-remitting multiple sclerosis patients is a challenging problem, which would benefit from a clinically valid decision support. Stühler et al. presented black box models for this aim which were developed and internally evaluated in a German …

nl, de (code pays fourni par la source)

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study

Antonios Bayas, Ulrich Mansmann, Begüm Irmak Ön, Verena Sophia Hoffmann et autres

INTRODUCTION: In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking. Cohort studies allow a close follow-up of MS histories and a thorough phenotyping of patients. Therefore, a multicenter cohort study was …

de (code pays fourni par la source)

Individual level surrogacy of MRI T2 lesion information for future disease severity: a methodological discussion and application to recent MS Phase II and III trials

Stefan Buchka, Havla Joachim, Begüm Irmak Ön, Raphael Rehms et autres

nl, de, sk (code pays fourni par la source)

Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis

Kelly A. Reeve, Begüm Irmak Ön, Joachim B. Havla, Jacob Burns et autres

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that affects millions of people worldwide. The disease course varies greatly across individuals and many disease-modifying treatments with different safety and efficacy profiles have been developed recently. Prognostic …

ch, de (code pays fourni par la source)

Framework for Personalized Prediction of Treatment Response in Relapsing-Remitting Multiple Sclerosis: A Replication Study in Independent Data

Anna Maria Sakr, Ulrich Mansmann, Joachim B. Havla, Begüm Irmak Ön

nl, de, sk (code pays fourni par la source)

Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis

Alexander Hapfelmeier, Begüm Irmak Ön, Mark Mühlau, Jan Stefan Kirschke et autres

Background: Multiple sclerosis (MS) is a chronic neuroinflammatory disease affecting about 2.8 million people worldwide. Disease course after the most common diagnoses of relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) is highly variable and cannot be reliably predicted. This impairs …

de (code pays fourni par la source)

Antidepressant use and stroke or mortality risk in the elderly

Begüm Irmak Ön, Xavier Vidal, Ursula Berger, Mònica Sabaté et autres

BACKGROUND AND PURPOSE: Current evidence on antidepressant-related stroke or mortality risk is inconsistent. Because the elderly have the highest exposure to antidepressants, the aim was to quantify their association with stroke and mortality risks in this vulnerable population. METHODS: Persons over 65 …

de, es (code pays fourni par la source)

Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis

Begüm Irmak Ön, Kelly A. Reeve, Joachim B. Havla, Jacob Burns et autres

OBJECTIVES: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: Primary objectives: To identify and summarize multivariable prognostic models for quantifying the risk of clinical disease progression, worsening, and activity in MS. To this end we will: …

de, ch (code pays fourni par la source)